Despite its clinical importance, due to the failure of several clinical trials with pro-angiogenic factors such as VEGF, FGF, and HGF in MI patients, currently available strategies for therapeutic vascular regeneration are very limited. This evidence concerns the gene VEGFA and myocardial infarction.